News
Novartis/Incyte draw blank with Jakafi in COVID-19
Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 tria
